{
  "screened_ideas": [
    {
      "date": "2025-12-30",
      "ticker": "TVTX",
      "company": "Travere Therapeutics",
      "archetype": "pdufa",
      "event_id": "EVT-2026-002",
      "kill_screens_passed": false,
      "failed_screens": [
        {
          "screen": "Beneish M-Score",
          "value": -1.15,
          "threshold": -1.78,
          "operator": "<=",
          "result": "FAIL - Indicates potential earnings manipulation"
        },
        {
          "screen": "Altman Z-Score",
          "value": 1.01,
          "threshold": 1.81,
          "operator": ">=",
          "result": "FAIL - Company in financial distress zone"
        }
      ],
      "result": "PASS",
      "reason": "Failed kill screens: M-Score -1.15 (manipulation risk) and Z-Score 1.01 (bankruptcy risk)"
    },
    {
      "date": "2025-12-30",
      "ticker": "RNA",
      "company": "Avidity Biosciences",
      "archetype": "merger_arb",
      "event_id": "EVT-2026-008",
      "kill_screens_passed": false,
      "failed_screens": [
        {
          "screen": "Beneish M-Score",
          "value": 8.32,
          "threshold": -1.78,
          "operator": "<=",
          "result": "FAIL - Indicates potential earnings manipulation"
        },
        {
          "screen": "Merger Spread",
          "value": "0.24%",
          "threshold": "2.5%",
          "operator": ">=",
          "result": "FAIL - Spread too narrow, historical return only 0.9%"
        }
      ],
      "passed_screens": [
        {
          "screen": "Altman Z-Score",
          "value": 23.11,
          "threshold": 1.81,
          "operator": ">=",
          "result": "PASS - Strong financial health"
        },
        {
          "screen": "Hostile Deal",
          "value": false,
          "threshold": "Must not be hostile",
          "result": "PASS - Friendly deal, boards unanimously approved"
        }
      ],
      "result": "PASS",
      "reason": "Failed kill screens: M-Score 8.32 (manipulation risk) and merger spread 0.24% (too narrow, <2.5% threshold)",
      "deal_details": {
        "acquirer": "Novartis",
        "deal_price": "$72.00",
        "current_price": "$71.83",
        "spread": "0.24%",
        "deal_value": "$12B",
        "expected_close": "H1 2026",
        "regulatory_status": "FTC early termination granted Dec 17, 2025"
      }
    },
    {
      "date": "2025-12-30",
      "ticker": "CMCSA",
      "company": "Comcast Corporation",
      "archetype": "spinoff",
      "event_id": "EVT-2026-012",
      "kill_screens_passed": false,
      "failed_screens": [
        {
          "screen": "Altman Z-Score",
          "value": 1.53,
          "threshold": 1.81,
          "operator": ">=",
          "result": "FAIL - Below distress threshold",
          "caveat": "IMPORTANT: Altman Z-Score designed for manufacturing firms, not applicable to telecom/media. May be false positive."
        }
      ],
      "passed_screens": [
        {
          "screen": "Beneish M-Score",
          "value": -2.79,
          "threshold": -1.78,
          "operator": "<=",
          "result": "PASS - No manipulation concerns"
        }
      ],
      "result": "PASS",
      "reason": "Failed Z-Score kill screen (1.53 < 1.81). NOTE: Z-Score not designed for telecom/media companies - likely false positive given Piotroski F-Score of 9, strong ROE 24%, and healthy financials",
      "framework_note": "Potential framework limitation: Altman Z-Score may need industry-specific thresholds or exclusions for non-manufacturing sectors",
      "countervailing_evidence": {
        "piotroski_f_score": 9,
        "roe": "24.19%",
        "debt_to_equity": 1.02,
        "interest_coverage": "5.3x",
        "market_cap": "$108B",
        "financial_health": "Strong cash flow, debt well covered"
      },
      "spinoff_details": {
        "spinco": "Versant Media Group",
        "record_date": "2025-12-16",
        "distribution_date": "2026-01-02",
        "regular_trading_begins": "2026-01-05",
        "distribution_ratio": "1 Versant share per 25 Comcast shares",
        "tax_treatment": "Tax-free to shareholders"
      }
    },
    {
      "date": "2025-12-30",
      "ticker": "AKRO",
      "company": "Akero Therapeutics",
      "archetype": "merger_arb",
      "event_id": "EVT-2026-009",
      "kill_screens_passed": "N/A",
      "result": "COMPLETED",
      "reason": "Deal already closed on December 9, 2025. No longer an arbitrage opportunity.",
      "deal_details": {
        "acquirer": "Novo Nordisk",
        "deal_price": "$54.00",
        "current_price": "$54.65",
        "deal_value": "$4.7B upfront + $0.5B CVR",
        "announcement_date": "2025-10-09",
        "close_date": "2025-12-09",
        "status": "CLOSED - AKRO is now wholly-owned subsidiary of Novo Nordisk",
        "delisted": "Yes - no longer trading on Nasdaq",
        "cvr_terms": "$6 per share upon EFX regulatory approval for MASH by June 30, 2031"
      },
      "note": "Stock trading at $54.65 reflects $54 deal price plus CVR value. Deal completed before analysis could be performed."
    },
    {
      "date": "2025-12-30",
      "ticker": "AQST",
      "company": "Aquestive Therapeutics",
      "archetype": "pdufa",
      "event_id": "EVT-2026-001, EVT-2026-003",
      "kill_screens_passed": false,
      "failed_screens": [
        {
          "screen": "Altman Z-Score",
          "value": -5.39,
          "threshold": 1.81,
          "operator": ">=",
          "result": "SEVERE FAIL - Extreme financial distress, well below critical threshold"
        }
      ],
      "passed_screens": [],
      "result": "PASS",
      "reason": "Failed Z-Score kill screen (-5.39 << 1.81). Extreme financial distress with high bankruptcy probability. Z-Score below -1.0 indicates severe risk.",
      "additional_red_flags": {
        "piotroski_f_score": 1,
        "negative_equity": "-$72.59M",
        "book_value_per_share": "-$0.73",
        "free_cash_flow_ttm": "-$50.02M",
        "net_loss_ttm": "-$65.04M",
        "cash_burn_rate": "Very high - burning through cash rapidly",
        "current_ratio": 3.5,
        "net_cash_position": "$20.28M"
      },
      "pdufa_details": {
        "product_1": "AQST-109 (epinephrine)",
        "pdufa_date_1": "2026-01-06",
        "review_type_1": "Standard",
        "product_2": "Anaphylm (epinephrine sublingual film)",
        "pdufa_date_2": "2026-01-31",
        "review_type_2": "Priority",
        "indication": "Emergency treatment of severe allergic reactions/anaphylaxis",
        "adcom_status": "Not required - FDA confirmed no Advisory Committee needed",
        "commercial_readiness": "Preparing for Q1 2026 launch if approved"
      },
      "framework_note": "Despite promising product (first oral epinephrine) and imminent PDUFA decisions, severe financial distress disqualifies. Z-Score of -5.39 is catastrophic."
    },
    {
      "date": "2025-12-30",
      "ticker": "ASND",
      "company": "Ascendis Pharma",
      "archetype": "pdufa",
      "event_id": "EVT-2026-004",
      "kill_screens_passed": false,
      "failed_screens": [
        {
          "screen": "Beneish M-Score",
          "value": -1.1,
          "threshold": -1.78,
          "operator": "<=",
          "result": "FAIL - Indicates potential earnings manipulation"
        }
      ],
      "passed_screens": [
        {
          "screen": "Altman Z-Score",
          "value": 5.23,
          "threshold": 1.81,
          "operator": ">=",
          "result": "PASS - Strong financial health (improved from 1.74 distress in Oct 2025)"
        }
      ],
      "result": "PASS",
      "reason": "Failed M-Score kill screen (-1.1 > -1.78 threshold). However, this may be false positive given company just achieved first quarterly operating profit in Q3 2025.",
      "framework_note": "Potential false positive: M-Score concern may reflect rapid transition from development-stage to profitable commercial company rather than manipulation",
      "countervailing_evidence": {
        "z_score_improvement": "Improved from 1.74 (distress, Oct 2025) to 5.23 (strong, Dec 2025)",
        "q3_2025_milestone": "First quarterly operating profit (€11M)",
        "revenue_growth": "€214M Q3 2025 vs €58M Q3 2024 (4x growth)",
        "commercial_products": "YORVIPATH (€143M), SKYTROFA (€51M)",
        "cash_position": "€539M ($585M)",
        "market_cap": "$12.83B (large-cap)",
        "current_ratio": 1.03,
        "net_loss_improving": "€61M Q3 2025 vs €99M Q3 2024 (38% improvement)"
      },
      "pdufa_details": {
        "product": "TransCon CNP (navepegritide)",
        "pdufa_date": "2026-02-28",
        "pdufa_date_note": "Extended from Nov 30, 2025 due to major amendment (post-marketing study protocol)",
        "review_type": "Priority",
        "indication": "Achondroplasia (rare disease - dwarfism)",
        "clinical_data": "Significantly higher growth velocity at Week 52 vs placebo, improved limb alignment",
        "publication": "Pivotal ApproaCH Trial published in JAMA Pediatrics Nov 2025",
        "market_opportunity": "Third commercial product for company"
      },
      "investment_thesis_if_screens_passed": "Profitable rare disease company ($214M quarterly revenue) with two commercial products, strong balance sheet, and third product PDUFA in Feb 2026. Recent inflection to profitability. Large-cap biotech with sustained revenue growth."
    },
    {
      "date": "2025-12-30",
      "ticker": "ALDX",
      "company": "Aldeyra Therapeutics",
      "archetype": "pdufa",
      "event_id": "EVT-2026-005",
      "kill_screens_passed": "INCOMPLETE",
      "result": "INCOMPLETE ANALYSIS",
      "reason": "Unable to obtain Beneish M-Score and Altman Z-Score from public sources. Cannot verify kill screens without these metrics.",
      "framework_limitation": "M-Score and Z-Score not readily available for all small-cap biotech companies. May require manual calculation from SEC filings or premium data services.",
      "available_financial_data": {
        "total_assets": "$84.96M",
        "total_equity": "$49.25M (positive)",
        "cash": "$75.30M",
        "total_debt": "$15.54M",
        "debt_to_equity": 0.32,
        "quick_ratio": 5.6,
        "current_ratio": 2.72,
        "roe": "-64.31% (unprofitable)",
        "net_cash_position": "$59.75M",
        "cash_runway": "Through 2027",
        "eps_ttm": "-$0.73"
      },
      "financial_assessment": "Mixed: Strong liquidity and low leverage, but unprofitable with negative ROE. Not in severe distress but not financially strong either.",
      "pdufa_details": {
        "product": "Reproxalap",
        "pdufa_date": "2026-03-16",
        "pdufa_date_note": "Extended from Dec 16, 2025 after FDA requested Clinical Study Report from field trial",
        "review_type": "Complete Class 2 Response (3rd NDA submission)",
        "indication": "Dry eye disease",
        "clinical_data_concern": "Field trial did not meet primary endpoint, but company says supportive of activity",
        "regulatory_history": "Two prior Complete Response Letters (CRLs) - Nov 2023 and April 2025",
        "fda_label_status": "FDA shared draft label in early Dec; awaiting final labeling requests by Feb 16, 2026",
        "market_opportunity": "Large dry eye disease market, but competitive"
      },
      "red_flags": {
        "regulatory_setbacks": "Two prior CRLs - FDA stated April 2025 NDA 'failed to demonstrate efficacy'",
        "failed_field_trial": "Most recent field trial missed primary endpoint",
        "third_attempt": "This is 3rd NDA submission - persistence or futility?",
        "execution_risk": "If approved, limited cash ($75M) for commercial launch vs. competitors"
      },
      "recommendation": "Manual review required. Calculate M-Score and Z-Score from 10-Q filings before proceeding. High regulatory risk given two CRLs and failed field trial."
    },
    {
      "date": "2025-12-30",
      "ticker": "GSK",
      "company": "GlaxoSmithKline plc",
      "archetype": "pdufa",
      "event_id": "EVT-2026-007",
      "kill_screens_passed": true,
      "passed_screens": [
        {
          "screen": "Beneish M-Score",
          "value": -2.87,
          "threshold": -1.78,
          "operator": "<=",
          "result": "PASS - Low manipulation risk"
        },
        {
          "screen": "Altman Z-Score",
          "value": 1.86,
          "threshold": 1.81,
          "operator": ">=",
          "result": "PASS - Barely passes, in 'grey zone' (1.81-2.99)"
        }
      ],
      "result": "WATCHLIST",
      "watchlist_file": "universe/watchlist/GSK.md",
      "next_step": "Run 'score' skill to complete analysis",
      "framework_fit_warning": "⚠️ PASSES KILL SCREENS BUT QUESTIONABLE FRAMEWORK FIT",
      "framework_concerns": {
        "market_cap": "$98B (mega-cap)",
        "catalyst_materiality": "Orphan drug approval immaterial to company this size",
        "expected_impact": "1-3% upside on approval, 0-1% downside on rejection",
        "idiosyncratic_fit": "NO - Large-cap with diversified pipeline, not event-driven special situation",
        "better_suited_for": "Long-term fundamental investors, not catalyst traders"
      },
      "financial_summary": {
        "market_cap": "$98B",
        "q3_revenue": "$11.5B (+10% YoY)",
        "operating_profit_growth": "+11%",
        "cash_from_operations": "£2.5B/quarter",
        "free_cash_flow": "£1.2B/quarter",
        "net_debt": "£14.4B",
        "debt_to_equity": 1.10,
        "interest_coverage": "13.1x",
        "credit_quality": "Investment grade (S&P/Moody's rated)"
      },
      "pdufa_details": {
        "product": "Linerixibat",
        "pdufa_date": "2026-03-24",
        "indication": "Cholestatic pruritus in primary biliary cholangitis (PBC)",
        "mechanism": "IBAT inhibitor (first-in-class)",
        "designation": "Orphan drug",
        "phase_3_trial": "GLISTEN - positive results (n=238)",
        "market_size": "Small - rare disease (PBC affects ~200K globally)",
        "peak_sales_estimate": "Likely <$500M (orphan indication)"
      },
      "assessment": "First company to PASS both kill screens. However, mega-cap size makes single orphan drug approval immaterial. Doesn't fit idiosyncratic framework targeting underappreciated catalysts in smaller companies."
    },
    {
      "date": "2025-12-30",
      "ticker": "ALNY",
      "company": "Alnylam Pharmaceuticals, Inc.",
      "archetype": "pdufa",
      "event_id": "EVT-2026-018",
      "kill_screens_passed": true,
      "passed_screens": [
        {
          "screen": "Beneish M-Score",
          "value": -2.60,
          "threshold": -1.78,
          "operator": "<=",
          "result": "PASS - Low manipulation risk",
          "source": "SEC XBRL FY2023/FY2024; computed"
        },
        {
          "screen": "Altman Z-Score",
          "value": 6.13,
          "threshold": 1.81,
          "operator": ">=",
          "result": "PASS - Strong financial health",
          "source": "SEC XBRL FY2024 + Stooq price; computed"
        }
      ],
      "result": "WATCHLIST",
      "watchlist_file": "universe/watchlist/ALNY.md",
      "next_step": "Run 'score' skill to complete analysis",
      "notes": "M-Score and Z-Score computed using SEC XBRL data (FY2023/FY2024) and Stooq price. LVGI uses total liabilities as a proxy for debt due to missing debt tags."
    },
    {
      "date": "2025-12-30",
      "ticker": "LUV",
      "company": "Southwest Airlines Co.",
      "archetype": "activist",
      "event_id": "EVT-2026-029",
      "kill_screens_passed": true,
      "passed_screens": [
        {
          "screen": "Beneish M-Score",
          "value": -2.58,
          "threshold": -1.78,
          "operator": "<=",
          "result": "PASS - Low manipulation risk",
          "source": "SEC XBRL FY2023/FY2024; computed with operating cost proxies"
        },
        {
          "screen": "Altman Z-Score",
          "value": 2.03,
          "threshold": 1.81,
          "operator": ">=",
          "result": "PASS - Grey zone, but above distress threshold",
          "source": "SEC XBRL FY2024 + Stooq price; computed"
        }
      ],
      "result": "WATCHLIST",
      "watchlist_file": "universe/watchlist/LUV.md",
      "next_step": "Run 'score' skill to complete analysis",
      "notes": "M-Score uses OperatingCostsAndExpenses as a proxy for COGS and SG&A due to airline reporting. Total liabilities derived as LiabilitiesAndStockholdersEquity minus StockholdersEquity."
    },
    {
      "date": "2025-12-30",
      "ticker": "SPGI",
      "company": "S&P Global Inc.",
      "archetype": "spinoff",
      "event_id": "EVT-2026-023",
      "kill_screens_passed": true,
      "passed_screens": [
        {
          "screen": "Beneish M-Score",
          "value": -2.44,
          "threshold": -1.78,
          "operator": "<=",
          "result": "PASS - Low manipulation risk",
          "source": "SEC XBRL FY2022/FY2023; computed"
        },
        {
          "screen": "Altman Z-Score",
          "value": 5.10,
          "threshold": 1.81,
          "operator": ">=",
          "result": "PASS - Strong financial health",
          "source": "SEC XBRL FY2023 + Stooq price; computed"
        }
      ],
      "result": "WATCHLIST",
      "watchlist_file": "universe/watchlist/SPGI.md",
      "next_step": "Run 'score' skill to complete analysis",
      "notes": "FY2023 is the latest 10-K in SEC XBRL at time of pull."
    }
  ]
}
